Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies

被引:17
|
作者
Hager, ACM [1 ]
Ellmark, P [1 ]
Borrebaeck, CAK [1 ]
Furebring, C [1 ]
机构
[1] Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden
关键词
D O I
10.1046/j.1365-3083.2003.01271.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and interfering antibodies have been suggested as an effective approach for the treatment of lymphomas and autoimmune diseases. In this study we have profiled a panel of mouse antihuman CD40 monoclonal antibodies (MoAbs), regarding their CD40 binding affinity and epitope-specificity relative to the CD40L binding in relation to their cellular activating potential. Despite a rather similar domain-recognition profile, the MoAbs blocked the CD40L binding to a varying degree, with MoAb 5C3 being the poorest inhibitor. There was no correlation between affinity and cellular activation potential. In contrast, a correlation between the ability to block CD40L-binding and activation potential could be seen. We believe that this analysis of several mouse anti-CD40 antibodies can be used to develop strategies for producing new human anti-CD40 antibodies that can more effectively induce or block B-cell proliferation.
引用
收藏
页码:517 / 524
页数:8
相关论文
共 50 条
  • [21] Preliminary phase 1 evaluations of 2 anti-CD40 monoclonal antibodies in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 342 - 344
  • [22] Preliminary study of anti-CD40 and ubiquitin proteasome antibodies in primary podocytopaties
    Chebotareva, Natalia
    Cao, Venzsin
    Vinogradov, Anatoliy
    Alentov, Igor
    Sergeeva, Natalia
    Kononikhin, Alexey
    Moiseev, Sergey
    FRONTIERS IN MEDICINE, 2023, 10
  • [23] Selective FcγR engagement by human agonistic anti-CD40 antibodies
    Ellmark, Peter
    Mangsbo, Sara M.
    Lindstedt, Malin
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S839 - S841
  • [24] Anti-Cd40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus.
    Vlachoyiannopoulos, P
    Mavragani, C
    Balitsari, A
    Bourazopoulou, E
    Routsias, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S72 - S73
  • [25] HIV-specific responses induced by anti-CD40 targeting antibodies
    Loof, N.
    Montes, M.
    Flamar, A.
    Zurawski, G.
    Cobb, A.
    Plants, J.
    King, B.
    Zurawski, S.
    Sloan, L.
    Levy, Y.
    Banchereau, J.
    RETROVIROLOGY, 2009, 6
  • [26] Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
    White, Ann L.
    Chan, H. T. Claude
    Roghanian, Ali
    French, Ruth R.
    Mockridge, C. Ian
    Tutt, Alison L.
    Dixon, Sandra V.
    Ajona, Daniel
    Verbeek, J. Sjef
    Al-Shamkhani, Aymen
    Cragg, Mark S.
    Beers, Stephen A.
    Glennie, Martin J.
    JOURNAL OF IMMUNOLOGY, 2011, 187 (04): : 1754 - 1763
  • [27] T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
    Tutt, AL
    O'Brien, L
    Hussain, A
    Crowther, GR
    French, RR
    Glennie, MJ
    JOURNAL OF IMMUNOLOGY, 2002, 168 (06): : 2720 - 2728
  • [28] In Vivo Characterization of a Novel Recombinant Anti-CD40 Monoclonal Antibody in Nonhuman Primates
    Badell, I. R.
    Mendel, J. B.
    Robertson, J. M.
    Johnson, B. E.
    Wang, X.
    Wang, R.
    Iwakoshi, N. N.
    Reimann, K. A.
    Kirk, A. D.
    Larsen, Christian P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 214 - 214
  • [29] Anti-CD40 monoclonal antibody therapy: Treatment toxicity and implications for cancer immunotherapy
    Geldart, T
    Harvey, M
    Carr, N
    Glennie, M
    Johnson, P
    BRITISH JOURNAL OF CANCER, 2003, 88 : S36 - S36
  • [30] Combination of Anti-CD40 and Anti-CD40L Antibodies as Co-Stimulation Blockade in Preclinical Cardiac Xenotransplantation
    Bender, Martin
    Abicht, Jan-Michael
    Reichart, Bruno
    Neumann, Elisabeth
    Radan, Julia
    Mokelke, Maren
    Buttgereit, Ines
    Leuschen, Maria
    Wall, Felicia
    Michel, Sebastian
    Ellgass, Reinhard
    Steen, Stig
    Paskevicius, Audrius
    Lange, Andreas
    Kessler, Barbara
    Kemter, Elisabeth
    Klymiuk, Nikolai
    Denner, Joachim
    Godehardt, Antonia W.
    Toenjes, Ralf R.
    Burgmann, Jonathan M.
    Figueiredo, Constanca
    Milusev, Anastasia
    Zollet, Valentina
    Salimi-Afjani, Neda
    Despont, Alain
    Rieben, Robert
    Ledderose, Stephan
    Walz, Christoph
    Hagl, Christian
    Ayares, David
    Wolf, Eckhard
    Schmoeckel, Michael
    Brenner, Paolo
    Binder, Uli
    Gebauer, Michaela
    Skerra, Arne
    Laengin, Matthias
    BIOMEDICINES, 2024, 12 (08)